×

Albumin fusion proteins

  • US 20050054570A1
  • Filed: 02/11/2004
  • Published: 03/10/2005
  • Est. Priority Date: 12/21/2001
  • Status: Active Grant
0
Associated Cases
0
Associated Defendants
0
Product Citations
0
Petitions
73
Forward Citations
2
Assignments
First Claim
Patent Images

1. An albumin fusion protein comprising a member selected from the group consisting of:

  • (a) a Therapeutic protein;

    X and albumin comprising the amino acid sequence of SEQ ID NO;

    1038;

    (b) a Therapeutic protein;

    X and a fragment or a variant of the amino acid sequence of SEQ ID NO;

    1038, wherein said fragment or variant has albumin activity;

    (c) a Therapeutic protein;

    X and a fragment or a variant of the amino acid sequence of SEQ ID NO;

    1038, wherein said fragment or variant has albumin activity, and further wherein said albumin activity is the ability to prolong the shelf life of the Therapeutic protein;

    X compared to the shelf-life of the Therapeutic protein;

    X in an unfused state;

    (d) a Therapeutic protein;

    X and a fragment or a variant of the amino acid sequence of SEQ ID NO;

    1038, wherein said fragment or variant has albumin activity, and further wherein the fragment or variant comprises the amino acid sequence of amino acids 1-387 of SEQ ID NO;

    1038;

    (e) a fragment or variant of a Therapeutic protein;

    X and albumin comprising the amino acid sequence of SEQ ID NO;

    1038, wherein said fragment or variant has a biological activity of the Therapeutic protein;

    X;

    (f) a Therapeutic protein;

    X, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (e), wherein the Therapeutic protein;

    X, or fragment or variant thereof, is fused to the N-terminus of albumin, or the N-terminus of the fragment or variant of albumin;

    (g) a Therapeutic protein;

    X, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (e), wherein the Therapeutic protein;

    X, or fragment or variant thereof, is fused to the C-terminus of albumin, or the C-terminus of the fragment or variant of albumin;

    (h) a Therapeutic protein;

    X, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (e), wherein the Therapeutic protein;

    X, or fragment or variant thereof, is fused to the N-terminus and C-terminus of albumin, or the N-terminus and the C-terminus of the fragment or variant of albumin;

    (i) a Therapeutic protein;

    X, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (e), which comprises a first Therapeutic protein;

    X, or fragment or variant thereof, and a second Therapeutic protein;

    X, or fragment or variant thereof, wherein said first Therapeutic protein;

    X, or fragment or variant thereof, is different from said second Therapeutic protein;

    X, or fragment or variant thereof;

    (j) a Therapeutic protein;

    X, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (i), wherein the Therapeutic protein;

    X, or fragment or variant thereof, is separated from the albumin or the fragment or variant of albumin by a linker;

    (k) a Therapeutic protein;

    X, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (j), wherein the albumin fusion protein has the following formula;


    R1-L-R2;

    R2-L-R1;

    or R1-L-R2-L-R1, and further wherein R1 is Therapeutic protein;

    X, or fragment or variant thereof, L is a peptide linker, and R2 is albumin comprising the amino acid sequence of SEQ ID NO;

    1038 or a fragment or variant of albumin;

    (l) a Therapeutic protein;

    X, or fragment or variant thereof, inserted into an albumin, or fragment or variant thereof, comprising the amino acid sequence of SEQ ID NO;

    1038 or fragment or variant thereof;

    (m) a Therapeutic protein;

    X, or fragment or variant thereof, inserted into an albumin, or fragment or variant thereof, comprising an amino acid sequence selected from the group consisting of;

    (i) amino acids 54 to 61 of SEQ ID NO;

    1038;

    (ii) amino acids 76 to 89 of SEQ ID NO;

    1038;

    (iii) amino acids 92 to 100 of SEQ ID NO;

    1038;

    (iv) amino acids 170 to 176 of SEQ ID NO;

    1038;

    (v) amino acids 247 to 252 of SEQ ID NO;

    1038;

    (vi) amino acids 266 to 277 of SEQ ID NO;

    1038;

    (vii) amino acids 280 to 288 of SEQ ID NO;

    1038;

    (viii) amino acids 362 to 368 of SEQ ID NO;

    1038;

    (ix) amino acids 439 to 447 of SEQ ID NO;

    1038;

    (x) amino acids 462 to 475 of SEQ ID NO;

    1038;

    (xi) amino acids 478 to 486 of SEQ ID NO;

    1038; and

    (xii) amino acids 560 to 566 of SEQ ID NO;

    1038;

    (n) two or more tandemly oriented Therapeutic protein;

    X polypeptides, or fragments or variants thereof, fused to the N-terminus of an albumin comprising the amino acid sequence of SEQ ID NO;

    1038 or fragment or variant thereof; and

    (o) two or more tandemly oriented Therapeutic protein;

    X polypeptides, or fragments or variants thereof, fused to the C-terminus of an albumin comprising the amino acid sequence of SEQ ID NO;

    1038 or fragment or variant thereof.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×